Filana Therapeutics (FLNA) Return on Capital Employed (2011 - 2026)
Filana Therapeutics (FLNA) posted quarterly Return on Capital Employed of 69.68% for Q2 2026, up 7355.0% year-over-year from 0.93% in Q2 2025, and up 37.74% quarter-over-quarter from 111.91% in Q1 2026.
Filana Therapeutics (FLNA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Filana Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 69.68% for Q2 2026.
- In Q2 2026, Return on Capital Employed rose 7355.0% year-over-year to 69.68%; the TTM figure through Jun 2026 stood at 69.68% (up 7355.0% YoY), while the FY2025 annual figure was 101.36%, down 234.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 69.68%, up from 111.91% in the prior quarter.
- The five-year high for Return on Capital Employed was 18.96% in Q1 2022, with the low at 143.23% in Q2 2025.
- The 5-year median for Return on Capital Employed is 73.97% (2023), against an average of 78.04%.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed tumbled 8806 bps in 2024, then soared 7355 bps in 2026.
- Filana Therapeutics' Return on Capital Employed stood at 37.39% in 2022, then tumbled by 92 bps to 71.64% in 2023, then dropped by 10 bps to 79.07% in 2024, then slumped by 50 bps to 118.93% in 2025, then surged by 41 bps to 69.68% in 2026.
- Business Quant data shows FLNA's Return on Capital Employed at 69.68% in Q2 2026, 111.91% in Q1 2026, and 118.93% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - | -69.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.68% |
| Mar 31, 2026 | -111.91% |
| Dec 31, 2025 | -118.93% |
| Sep 30, 2025 | -131.73% |
| Jun 30, 2025 | -143.23% |
| Mar 31, 2025 | -107.43% |
| Dec 31, 2024 | -79.07% |
| Sep 30, 2024 | -76.29% |
| Jun 30, 2024 | -91.01% |
| Mar 31, 2024 | -129.79% |
| Dec 31, 2023 | -71.64% |
| Sep 30, 2023 | -62.16% |
| Jun 30, 2023 | -51.41% |
| Mar 31, 2023 | -41.73% |
| Dec 31, 2022 | -37.39% |
| Sep 30, 2022 | -35.18% |
| Jun 30, 2022 | -27.28% |
| Mar 31, 2022 | -18.96% |
| Dec 31, 2021 | -12.74% |
| Sep 30, 2021 | -7.75% |